Work

Study of the alterations of mineral metabolism and bone disorders associated with chronic kidney disease

Year: 2019
Type: dissertation
Abstract: Chronic Kidney Disease (CKD) affects million people worldwide and is a risk factor for morbidity and mortality. CKD patients have poor bone mineral density due to mineral metabolism imbalance and secondary hyperparathyroidism resulting in an increased fracture incidence. Bone, despite its well-known function on mineral storage and organ protection, plays an important role as endocrine organ controlling several system functions and metabolic pathways. In this respect, bone status have been associated with cardiovascular diseases and mortality in both, the general and CKD populations. Moreover, Fibroblast Growth Factor 23 (FGF23), a phosphaturic hormone secreted by osteocytes and mature osteoblasts has been associated with increased mortality and left ventricular hypertrophy. In clinical practice, mineral abnormalities are commonly treated with calcitriol, phosphate binders and calcimimetics, to maintain plasma parathyroid hormone (PTH) and phosphate levels within the normal range. Among the distinct types of phosphate binders available, those based on magnesium have additional benefits, preventing vascular smooth muscle cells calcification. As bone disorders are involved in adverse outcomes, we consider of interest the study of the abnormalities of mineral and bone disorders associated with CKD and \nhow calcitriol, magnesium, calcimimetic and FGF23 affect bone cells and bone homeostasis in the context of renal insufficiency. To address this issue we used animal models of renal insuficiency and in vitro models of osteoblasts and osteoclasts and we found that 1) moderate doses of calcitriol decrease osteoblast acitivity and increase mineralization in vivo whereas high doses of calcitriol impair osteogenic differentiation in vitro; 2) dietary magnesium supplementation increases osteoblast activity and may impair mineralization in vivo and magnesium supplementation promotes osteogenic differentiation in vitro through Notch signaling activation; 3) treatment with calcimimetic maintains bone turnover despite the concomitant decrease in PTH concentration in vivo and increased steogenesis and mineralization in vitro and 4) high FGF23 concentrations produce bone changes in a model of uni-nefrectomized rats and impair osteocyte maturation whereas promote osteoclast differentiation in vitro. Altogether, our results demonstrate a potential role of these molecules on bone homeostasis in CKD by targeting directly bone cells.
Authors: Díaz Tocados, Juán Manuel
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: green
OpenAlex ID: W2912454654
Cites: 296
Cited by:
Related to: 10